Bio-Outsourcing

Increased demand for CDMO microbial outsourcing services

18-Nov-2021 By Jane Byrne

Biotech innovators are looking to CDMOs for their key microbial expertise in order to move their therapies from lab to the market, says Lonza.

Alleviating CGT bottlenecks: Standards needed to ensure volumes, quality of starting material

12-Nov-2021 By Jane Byrne

Be the Match BioTherapies (BTMB) says it is critical that resilient cell sourcing infrastructures exist when cell and gene therapies (CGT) surge to market.

Touchlight set to break ground on world’s highest-capacity DNA manufacturing facility

18-Oct-2021 By Jane Byrne

Touchlight, a synthetic DNA producer, says it has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK.

New Merck viral vector CDMO plant opens in California

14-Oct-2021 By Jane Byrne

Merck and subsidiary MilliporeSigma have completed work on their second Carlsbad, California-based facility.

Fujifilm Diosynth in tie-up with US AAV gene therapy developer

14-Oct-2021 By Jane Byrne

LEXEO Therapeutics, a clinical-stage gene therapy company, is partnering with CDMO, Fujifilm Diosynth Biotechnologies (FDB), to support the development and manufacturing of its AAV-mediated gene therapies.

Aceto makes further inroads into biopharma space, buys up A&C Bio Buffer

12-Oct-2021 By Jane Byrne

Aceto expands GMP product lines for biopharmaceutical and vaccine manufacturing with acquisition of A&C Bio Buffer, growing its manufacturing footprint and strengthening its presence in Europe.

Lonza invests in Singapore to support growth in mammalian biologics

11-Oct-2021 By Jane Byrne

Lonza is investing to expand mammalian development services at its Singapore facility; the move will bring additional capacity for cell culture, purification, and analytical services for mammalian biologics.

Samsung Biologics to help Enzolytics advance clinical development of mAbs

11-Oct-2021 By Jane Byrne

Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.

DNA plasmid manufacturer taking orders for mid-2022 production slots at new site

05-Oct-2021 By Jane Byrne

VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.

Pharma CEO confidence tops pre-pandemic levels, companies look to nucleic-acid technology assets to fuel growth

30-Sep-2021 By Jane Byrne

CEOs at large pharma and biotech companies are upbeat when it comes to their outlook for both their own company and the industry at large; they also have a healthy appetite for M&A, found a KPMG survey.

Intravacc looks to contract research, intranasal and cancer vaccine pipeline as revenue drivers

20-Sep-2021 By Jane Byrne

Dutch group, Intravacc, has launched a hybrid business model that it believes will fuel growth and innovation.

3i invests in new Switzerland based biologics-focused CDMO

13-Sep-2021 By Jane Byrne

3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).

Japan to take 150m doses of Takeda-produced Novavax shots, probe ongoing into deaths following inoculation with recalled Moderna vaccine lot

08-Sep-2021 By Jane Byrne

Japan’s health ministry is to secure 150 million doses of Novavax’ vaccine candidate that Takeda is producing. The Japanese government's purchasing agreement is subject to regulatory approvals.

Ardena buys Spain’s Idifarma in move to capitalize on emerging biotech segment

06-Sep-2021 By Jane Byrne

Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.

Eurofarma to manufacture Pfizer-BioNTech COVID-19 shot for Latin American market: Production set to exceed 100 million doses annually

26-Aug-2021 By Jane Byrne

Brazil’s Eurofarma Laboratórios SA is to manufacture Pfizer and BioNTech's COVID-19 vaccine, Comirnaty, for distribution within Latin America.

COVID-19 vaccine manufacturers show ‘sizable demand’ for vials out to 2023

16-Aug-2021 By Nick Taylor

There is “sizable demand” from manufacturers of COVID-19 vaccines for vials out to 2023, suggesting that the market will remain significant for some time.

WTO lists critical inputs for COVID-19 vaccines to address gaps in global supply

05-Aug-2021 By Nick Taylor

The World Trade Organization (WTO) Secretariat has published a list of critical inputs for COVID-19 vaccines as part of an effort to address gaps in global production and distribution of the products.

Cytiva and Pall to spend $1.5bn on manufacturing capacity expansion, new hires

27-Jul-2021 By Jane Byrne

Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally

Biotech Absci sees shares soar in IPO debut

27-Jul-2021 By Jane Byrne

Absci Corp, a Vancouver, Washington headquartered synthetic biology company developing technologies to accelerate drug discovery, has gone public.

Pall inks $7m deal with Exothera for suspension based production of viral vectors

19-Jul-2021 By Jane Byrne

Filtration, separation and purification specialist, Pall, has announced a new contract valued at over US$7M with full-service CDMO, Exothera.

GentiBio and Forge Biologics in viral vector contract development and GMP manufacturing partnership

19-Jul-2021 By Jane Byrne

Boston headquartered biotherapeutics company, GentiBio, Inc, and CGT focused CDMO, Forge Biologics, have set up a development and manufacturing partnership.

Ardena ploughs €35m into sites to future proof CDMO services

15-Jul-2021 By Jane Byrne

Ardena is investing €35m (US$41.3m) in expansion projects across its European operations.

Fujifilm continues to expand its biologics CDMO business, ploughing further $850m into US and UK sites

08-Jul-2021 By Jane Byrne

Fujifilm Corporation has made an additional US$850m investment to enable the expansion of its BIO-CMDO sites in the UK, at Billingham, and in the US.

Novasep secures manufacturing deal with US biotech for ADC drug candidate

06-Jul-2021 By Jane Byrne

Novasep has signed a manufacturing services agreement with Exelixis, an oncology-focused US biotechnology company, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC).

Belgian cell therapy firm signs €16m loan with EIB for development of orthopedic treatments

06-Jul-2021 By Jane Byrne

Cell therapy player, Bone Therapeutics, has secured up to €16m (US$18.9m) in a financing loan from the European Investment Bank (EIB) to accelerate ongoing clinical and commercial development of innovative orthopedic treatments.

Cobra flags successful production of plasmids for epilepsy targeted gene therapy

30-Jun-2021 By Jane Byrne

Cobra Biologics, the gene therapy division of the Charles River owned Cognate BioServices, and Sweden's CombiGene recently announced the successful production and quality assurance of the plasmids to be used in the GMP production of the gene therapy,...

Genezen breaks ground on cGMP lentiviral vector production facility

28-Jun-2021 By Jane Byrne

Genezen Laboratories, Inc, a US cell and gene therapy contract development and manufacturing Organization (CDMO) is set to build a 75,000+ square foot cGMP-compliant lentiviral vector production facility in Indianapolis.

Lonza to provide manufacturing for ValenzaBio from China facility

23-Jun-2021 By Ben Hargreaves

Lonza will provide drug substance and product manufacturing for the biotech’s anti-IGF-1R antibody.

BIO DIGITAL 2021

BIO Digital lands at a time of ‘unprecedented industry collaboration’

02-Jun-2021 By Jenni Spinner

The online pharma event will address the COVID-19 pandemic’s impact on the industry (and vice versa) and innovation in the face of formidable challenges.

Merck rolls out new lipid technology nine months ahead of schedule

27-May-2021 By Jane Byrne

Germany’s Merck KGaA has launched a new synthetic cholesterol product that it says will boost capacity for its lipid delivery tools by 50 times.

New BD plant set for Spain aims to meet growing demand for PFS

20-May-2021 By Jane Byrne

Becton, Dickinson and Company (BD) is to build a new plant in Zaragoza, Spain, with an investment of €165m (US$200m). The site will produce glass pre-filled syringes and plastic components.

Acquisition boosts Charles River's viral vector, AAV and plasmid DNA production expertise

18-May-2021 By Jane Byrne

Charles River Laboratories International Inc is to acquire US based Vigene Biosciences, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions for research and clinical...

GSK and Sanofi report positive data from COVID-19 vaccine candidate trial: Strong immune responses seen in adults of all ages

17-May-2021 By Jane Byrne

Sanofi and GSK announced today that their COVID-19 vaccine candidate demonstrated strong immune responses across all adult age groups in a Phase 2 trial.

Novasep expands in France, sees increasing customer demand for ADC manufacturing services

14-May-2021 By Jane Byrne

Novasep has announced a further expansion of its Highly Potent Active Pharmaceutical Ingredients (HPAPIs) manufacturing capabilities at its Le Mans, France site, saying the move strengthens its position as a leading CDMO for the production of innovative...

Special Edition: Continuous bioprocessing

Continuous bioprocessing market to be worth nearly $200m within six years

06-May-2021 By Jane Byrne

A new report published by Meticulous Research shows the continuous bioprocessing market is expected to grow at a CAGR of 22.9% from 2020 to 2027 to reach US$197.8m by the end of the period.

Clean Biologics gains foothold in North American market, adds vaccine and biologics focused CDMO to group

05-May-2021 By Jane Byrne

French pharma services provider, Clean Biologics, has acquired Canadian CDMO, Biodextris, in a move it says will boost its analytical and process development, and early-phase clinical manufacturing and quality control testing services for clients in the...

BioPharma-Reporter

Resources